| HOME >> MEDICINE >> TECHNOLOGY |
4.5.4 Public Health Advantage 13
4.5.5 Cost Effectiveness 13
4.5.6 Barriers to the Vaccination 13
4.6 Vaccine Evaluation 14
4.6.1 Efficacy 14
4.6.2 Safety 14
4.6.3 Dosing Convenience 15
4.6.4 Intensity of Competition 15
4.7 Sales forecast 16
4.7.1 Eligible population for Gardasil 16
4.7.2 Dosing 16
4.7.3 Market Penetration 16
4.7.4 Annual Cost of Therapy 17
4.7.5 Sales Projections of Gardasil 17
5 Cervical Cancer Vaccine Market: Appendix 24
5.1 Market Definitions 24
5.2 List of Abberiviations 24
5.3 Research Methodology 24
5.3.1 Coverage 25
5.3.2 Secondary Research 25
5.3.3 Forecasting 25
5.3.4 Population Approved to take Vaccine 26
5.3.5 Net Penetration of Vaccine 26
5.3.6 Net Annual Dosing 27
5.3.7 Annual Cost of Therapy 27
5.3.8 Primary Research 27
5.3.9 Expert Panels 27
5.4 Contact Us 27
5.5 Disclaimer 28
1.1 List of Tables
Table 1:Cervical Cancer, Estimated Incidences and Mortality, 2010-2020 5
Table 2: Estimated Prevalence of HPV in 9-26 years women 7
Table 3: Gardasil, Cervical Cancer Global, Sales Forecast ($m), 2006–2020 17
Table 4: Gardasil, Cervical Cancer, the US, Sales Forecast ($m), 2006–2020 18
Table 5: Gardasil, Cervical Cancer, UK, Sales Forecast ($m), 2006–2020 19
Table 6: Gardasil, Cervical Cancer, France, Sales Forecast ($m), 2006–2020 20
Table 7: Gardasil, Cervical Cancer, Germany, Sales Forecast ($m), 2006–2020 21
Table 8: Gardasil, Cervical Cancer, Italy, Sales Forecast ($m), 2006–2020 22
Table 9: Gardasil, Cervical Cancer, Spain, Sales Forecast ($m), 2006–2020 23
1.2 List of Figures
Figure 1: Estimated Prevalence of HPV in Women Aged between 9-26 Years in the US,EU-5 and Japan, 2010-2020 1
Figur
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |